U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H24N4O6
Molecular Weight 452.4599
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MERIMEPODIB

SMILES

COC1=C(C=CC(NC(=O)NC2=CC=CC(CNC(=O)O[C@H]3CCOC3)=C2)=C1)C4=CN=CO4

InChI

InChIKey=JBPUGFODGPKTDW-SFHVURJKSA-N
InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H24N4O6
Molecular Weight 452.4599
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800008158 http://files.shareholder.com/downloads/VRTX/3251874583x0xS912057-02-12962/875320/filing.pdf https://www.ncbi.nlm.nih.gov/pubmed/23016672

Merimepodib has immunosuppressive activity. It targets hepatitis C indirectly through the inhibition of inositol monophosphate dehydrogenase, which exerts an acute antiproliferative effect on lymphocyte proliferation due to their almost exclusive dependence on the de novo pathway for synthesis of guanosine. Phase II clinical trial study of merimepodib for the treatment of HCV infection and psoriasis were completed. The poor pharmacokinetic-pharmacodynamic results have resulted in discontinuation of clinical trials.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1748 ng/mL
100 mg 3 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3195 ng/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3543 ng × h/mL
100 mg 3 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8210 ng × h/mL
200 mg 3 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
MERIMEPODIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Novel approaches to the treatment of hepatitis C virus infection.
2000 Mar
Patents

Sample Use Guides

25 or 50 mg every 12h (24 weeks of treatment)
Route of Administration: Oral
The IC50 values for VX-497 in Sprague-Dawley or Lewis rat lymphocytes were similar to the 100 nM human PBMC IC50 values.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:30:06 UTC 2023
Edited
by admin
on Fri Dec 15 16:30:06 UTC 2023
Record UNII
2ZL2BA06FU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MERIMEPODIB
INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
MERIMEPODIB [USAN]
Common Name English
VX-497
Code English
CARBAMIC ACID, ((3-((((3-METHOXY-4-(5-OXAZOLYL)PHENYL)AMINO)CARBONYL)AMINO)PHENYL)METHYL)-, (3S)-TETRAHYDRO-3-FURANYL ESTER
Common Name English
(S)-TETRAHYDRO-3-FURYL (M-(3-(3-METHOXY-4-(5-OXAZOLYL)PHENYL)UREIDO)BENZYL)CARBAMATE
Systematic Name English
Merimepodib [WHO-DD]
Common Name English
VI-21,497
Code English
merimepodib [INN]
Common Name English
VI-21497
Code English
MERIMEPODIB [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
NCI_THESAURUS C2087
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C66097
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
MERCK INDEX
m7238
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY Merck Index
USAN
MM-03
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
WIKIPEDIA
Merimepodib
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
ChEMBL
CHEMBL304087
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
EPA CompTox
DTXSID70173639
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
CAS
198821-22-6
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
FDA UNII
2ZL2BA06FU
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
EVMPD
SUB34886
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
SMS_ID
100000128133
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
DRUG BANK
DB04862
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
PUBCHEM
153241
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
INN
8123
Created by admin on Fri Dec 15 16:30:06 UTC 2023 , Edited by admin on Fri Dec 15 16:30:06 UTC 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY